LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Bio-path Holdings Inc.
Headquarters:
Bellaire, TX, United States
Website:
http://www.biopathholdings.com...
Year Founded:
2007
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Peter H. Nielsen, MBA
Number Of Employees:
10
Enterprise Value:
$1,695,160
PE Ratio:
-0.02
Exchange/Ticker 1:
NASDAQ:BPTH
Exchange/Ticker 2:
N/A
Latest Market Cap:
$1,354,200
BioCentury
|
Apr 6, 2018
Clinical News
Bio-Path reports interim Phase II data for AML candidate
Read More
BioCentury
|
Nov 4, 2016
Clinical News
BP1001: Ph II started
Read More
BioCentury
|
Jul 18, 2016
Company News
Bio-Path, Thomas Jefferson University deal
Read More
BioCentury
|
Jul 11, 2016
Financial News
Bio-Path proposes direct public offering
Read More
BioCentury
|
Jun 13, 2016
Clinical News
Liposomal Grb-2: Additional Phase I data
Read More
BioCentury
|
Sep 7, 2015
Clinical News
Liposomal Grb-2: Phase I data
Read More
BioCentury
|
May 4, 2015
Clinical News
Liposomal Grb-2 regulatory update
Read More
BioCentury
|
Feb 16, 2015
Clinical News
Liposomal Grb-2: Phase II started
Read More
BioCentury
|
Apr 7, 2014
Company News
Bio-Path management update
Read More
BioCentury
|
Mar 17, 2014
Financial News
Bio-Path financial update
Read More
Items per page:
10
1 - 10 of 18